Tinnitus - Pipeline Review, H2 2016

Date: September 14, 2016
Pages: 62
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T8C3161AF78EN
Leaflet:

Download PDF Leaflet

Tinnitus - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Tinnitus - Pipeline Review, H2 2016’, provides an overview of the Tinnitus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tinnitus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Tinnitus
  • The report reviews pipeline therapeutics for Tinnitus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Tinnitus therapeutics and enlists all their major and minor projects
  • The report assesses Tinnitus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Tinnitus
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Tinnitus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tinnitus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Tinnitus Overview
Therapeutics Development
Pipeline Products for Tinnitus - Overview
Pipeline Products for Tinnitus - Comparative Analysis
Tinnitus - Therapeutics under Development by Companies
Tinnitus - Therapeutics under Investigation by Universities/Institutes
Tinnitus - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Tinnitus - Products under Development by Companies
Tinnitus - Products under Investigation by Universities/Institutes
Tinnitus - Companies Involved in Therapeutics Development
AudioCure Pharma GmbH
Auris Medical Holding AG
Knopp Biosciences LLC
Merz Pharma GmbH & Co. KgaA
Otonomy, Inc.
SciFluor Life Sciences, LLC
Sound Pharmaceuticals, Inc.
Tinnitus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AM-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Activate KCNQ for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esketamine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gacyclidine SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
neramexane mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-0034 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TNF-Alpha for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPI-1005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPI-3005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tinnitus - Dormant Projects
Tinnitus - Product Development Milestones
Featured News & Press Releases
Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus
Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million
Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus
Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus
Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus
Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City
Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus
Nov 16, 2015: Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311
Oct 05, 2015: Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
Jul 02, 2015: Auris Medical Holding Provides Update on U.S. Intellectual Property Portfolio
Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience
Apr 20, 2015: Auris Medical Announces Publications Related to AM-101 in Peer-Reviewed Scientific and Medical Journals
Mar 13, 2015: Auris Medical Announces Recently Granted Patent in India for the Treatment of Tinnitus
Mar 11, 2015: Auris Medical to Host Key Opinion Leader Meeting on Tinnitus Treatments on March 13 in New York City
Mar 10, 2015: Auris Medical Announces Completion of Interim Analysis in Post-Acute Tinnitus Stratum of TACTT3 Trial with AM-101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 62

LIST OF TABLES

Number of Products under Development for Tinnitus, H2 2016
Number of Products under Development for Tinnitus - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Tinnitus - Pipeline by AudioCure Pharma GmbH, H2 2016
Tinnitus - Pipeline by Auris Medical Holding AG, H2 2016
Tinnitus - Pipeline by Knopp Biosciences LLC, H2 2016
Tinnitus - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
Tinnitus - Pipeline by Otonomy, Inc., H2 2016
Tinnitus - Pipeline by SciFluor Life Sciences, LLC, H2 2016
Tinnitus - Pipeline by Sound Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Tinnitus - Dormant Projects, H2 2016 52

LIST OF FIGURES

Number of Products under Development for Tinnitus, H2 2016
Number of Products under Development for Tinnitus - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Tinnitus - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 65 pages
AudioCure Pharma GmbH - Product Pipeline Review - 2015 US$ 1,275.00 Nov, 2015 · 23 pages
ADC Therapeutics Sarl - Product Pipeline Review - 2015 US$ 1,200.00 Feb, 2015 · 26 pages
Gaucher Disease - Pipeline Review, H1 2016 US$ 2,000.00 Jun, 2016 · 78 pages

Ask Your Question

Tinnitus - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: